BofA moved to No Rating from Underperform on Sage Therapeutics (SAGE) after the company announced a definitive agreement to be acquired by Supernus Pharmaceuticals (SUPN) for a total up to $12 per share. Sage shares are no longer trading on fundamentals given the deal announcement, the analyst tells investors.